ClinicalTrials.gg
TerminatedNCT03254927Updated Apr 3, 2023Results posted

A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma

A Phase 2 interventional study of CDX-3379 and cetuximab in Advanced Head and Neck Squamous Cell Carcinoma, sponsored by Celldex Therapeutics. Terminated at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-03.

Sponsored by Celldex Therapeutics · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor decision based on emerging risk-benefit profile

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing cetuximab in Mouth Neoplasms — 3 open to participants now, 4 under way, 2 of them phase 3. Cetuximab · Mouth Neoplasms.

Enrollment
9th of 10
30 · median 44
Started
2018
the only one that year
Phase 2
7 of 10
2 open now
Registered
7th of 10
by date

Among the 10 studies testing cetuximab in Mouth Neoplasms, this one is the 9th largest by enrollment, is the only one that started in 2018, is one of 7 in phase 2, and was the 7th registered.

Mouth Neoplasms

447 studies on the registry are indexed under Mouth Neoplasms; 131 are open to participants now.

Browse Mouth Neoplasms studies →

Open to participants now

3 of the 10 studies testing cetuximab in Mouth Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Mouth Neoplasms studies recruiting now, 58 (60%) set no upper age limit and 23 (24%) stop at 75 or younger; 5 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing cetuximab in Mouth Neoplasms, or all of them as a file.
02

Study summary

This is a study to determine the clinical benefit (how well the drug works), safety and tolerability of combining CDX-3379 and cetuximab. The study will enroll patients with advanced head and neck squamous cell carcinoma who have previously received cetuximab and progressed.

Read the detailed description

CDX-3379 is a fully human monoclonal antibody that binds to a molecule called human epidermal growth factor receptor 3 (HER3 or ErbB3) found on certain cells and may act to promote anti-tumor effects.

Cetuximab is a human monoclonal antibody that blocks EGFR, a protein receptor that regulates cell growth.

This study will evaluate the safety, tolerability and efficacy of CDX-3379 in combination with cetuximab in patients with advanced head and neck squamous cell carcinoma who have previously received cetuximab and progressed.

Eligible patients that enroll in the study will be given the dose of 12 mg/kg CDX-3379 once every 3 weeks in combination with 400 mg/m2 cetuximab on the first day followed by weekly doses of 250 mg/m2 cetuximab.

Up to 45 patients will be enrolled. All patients enrolled in the study will be closely monitored to determine if there is a response to the treatment as well as for any side effects that may occur.

03

Conditions studied

  • Advanced Head and Neck Squamous Cell Carcinoma

Keywords

  • Erbitux
  • Cetuximab
  • Oral Cancer
  • Oropharyngeal cancer
  • Laryngeal cancer
  • Head and Neck Squamous Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed head and neck squamous cell carcinoma.
  2. Human papilloma virus (HPV) negative tumor.
  3. Prior treatment with a check-point inhibitor targeting , unless not a candidate.
  4. Prior treatment with cetuximab with tumor progression during or within 6 months after completing treatment.
  5. .
  6. ≥ 12 weeks.
  7. If of (male or female), agrees to practice an effective form of during study treatment and for at least 6 months following last treatment.
  8. Willingness to undergo a tumor prior to starting treatment (or if biopsy is not feasible, provide archival tissue).

Exclusion criteria

Exclusion Criteria:

  1. Previous treatment with CDX-3379 or other anti-ErbB3 targeted agents.
  2. Nasal, paranasal sinus, or nasopharyngeal carcinoma, aside from WHO Type I and II (keratinizing, non-EBV positive) nasopharyngeal carcinoma which will be allowed.
  3. Major surgery within 4 weeks prior to first dose of study treatment.
  4. Chemotherapy within 21 days or at least 5 half-lives (whichever is shorter) prior to first dose of study treatment.
  5. Monoclonal based therapies within 4 weeks (excluding cetuximab) and all other immunotherapy within 2 weeks prior to first dose of study treatment.
  6. Other prior , active within 3 years, except for localized prostate cancer, cervical carcinoma in situ, non-melanomatous carcinoma of the skin, stage 1 differentiated thyroid cancer or ductal carcinoma in situ of the breast.
  7. Active, untreated central nervous system .
  8. Active disease or documented history of autoimmune disease.
  9. Significant cardiovascular disease including CHF or poorly controlled hypertension.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    CDX-3379 and cetuximab

    During the treatment phase of the study, eligible patients will receive assigned treatments in 3 week cycles until progression.

    Drug: CDX-3379 and cetuximab

Interventions

  • DrugCDX-3379 and cetuximab

    Drug pages: CDX-3379 · Cetuximab

    Dose: 12 mg/kg CDX-3379 once every 3 weeks in combination with 400 mg/m2 cetuximab on the first day followed by weekly doses of 250 mg/m2 cetuximab.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate

    The percentage of patients who achieve a complete response or partial response per Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST version 1.1), Complete Response (CR) = disappearance of all target lesions and non-target lesions, Partial Response (PR), \>= 30% decrease in the sum of the longest diameter of target lesions with no progression in non-target lesions and no new lesions.

    Time frame: The proportion of evaluable patients who achieve a best overall response of complete or partial response according to RECIST 1.1 assessed up to 24 months.

Secondary outcomes

  1. Clinical Benefit Response (CBR)

    The percentage of patients who achieve best response of confirmed CR or PR, or stable disease (SD) for at least 12 weeks

    Time frame: Every 8 weeks, starting with first dose until disease progression, assessed up to approximately 2 years

  2. Duration of Response (DOR)

    The interval from which measurement criteria are first met for Complete Response (CR) or Partial Response (PR) until the first date that progressive disease is objectively documented

    Time frame: First occurrence of a documented objective response to disease progression or death (up to approximately 2 years)

  3. Progression-free Survival (PFS)

    The time from start of study drug to time of progression or death, whichever occurs first

    Time frame: From first dose to the first occurrence of disease progression or death due to any cause (up to approximately 2 years)

  4. Overall Survival (OS)

    The time from start of study drug to death

    Time frame: The time from start of study drug to death from any cause (up to approximately 2 years)

  5. Incidence of Adverse Events [Safety and Tolerability]

    Safety and tolerability of CDX-3379 in combination with cetuximab as determined by incidence and severity of adverse events. Percentage of patients reporting one or more adverse events.

    Time frame: Following at least one dose of study treatment through 30 days after last dose of CDX-3379.

  6. Tumor DNA Biomarkers.

    Tumor DNA biomarkers will be evaluated and assessed for correlation with clinical efficacy. Objective response rate for subset of patients with FAT1 positive tumor is reported.

    Time frame: Tumor tissue is obtained during screening window via single biopsy procedure.

07

Results

Posted Apr 3, 2023
Limitations and caveats
Study was terminated early due to unfavorable risk/benefit profile.

Participant flow

Participant flow — Overall Study
MilestoneCDX-3379 and Cetuximab
Started30
Completed30
Not completed0

Outcome measures

PrimaryObjective Response Rate

The percentage of patients who achieve a complete response or partial response per Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST version 1.1), Complete Response (CR) = disappearance of all target lesions and non-target lesions, Partial Response (PR), \>= 30% decrease in the sum of the longest diameter of target lesions with no progression in non-target lesions and no new lesions.

Time frame:
The proportion of evaluable patients who achieve a best overall response of complete or partial response according to RECIST 1.1 assessed up to 24 months.
Reported as:
Number · percentage of participants
Objective Response Rate
percentage of participantsCDX-3379 and Cetuximab
Objective Response Rate7 (0.8 to 22.1)
SecondaryClinical Benefit Response (CBR)

The percentage of patients who achieve best response of confirmed CR or PR, or stable disease (SD) for at least 12 weeks

Time frame:
Every 8 weeks, starting with first dose until disease progression, assessed up to approximately 2 years
Reported as:
Number · percentage of participants
Clinical Benefit Response (CBR)
percentage of participantsCDX-3379 and Cetuximab
Clinical Benefit Response (CBR)40 (22.7 to 59.4)
SecondaryDuration of Response (DOR)

The interval from which measurement criteria are first met for Complete Response (CR) or Partial Response (PR) until the first date that progressive disease is objectively documented

Time frame:
First occurrence of a documented objective response to disease progression or death (up to approximately 2 years)
Reported as:
Number · months
Duration of Response (DOR)
monthsCDX-3379 and Cetuximab
Duration of Response (DOR)NA
SecondaryProgression-free Survival (PFS)

The time from start of study drug to time of progression or death, whichever occurs first

Time frame:
From first dose to the first occurrence of disease progression or death due to any cause (up to approximately 2 years)
Reported as:
Median · months
Progression-free Survival (PFS)
monthsCDX-3379 and Cetuximab
Progression-free Survival (PFS)2.2 (1.3 to 3.6)
SecondaryOverall Survival (OS)

The time from start of study drug to death

Time frame:
The time from start of study drug to death from any cause (up to approximately 2 years)
Reported as:
Median · months
Overall Survival (OS)
monthsCDX-3379 and Cetuximab
Overall Survival (OS)6.6 (2.7 to 7.5)
SecondaryIncidence of Adverse Events [Safety and Tolerability]

Safety and tolerability of CDX-3379 in combination with cetuximab as determined by incidence and severity of adverse events. Percentage of patients reporting one or more adverse events.

Time frame:
Following at least one dose of study treatment through 30 days after last dose of CDX-3379.
Reported as:
Count of participants · Participants
Incidence of Adverse Events [Safety and Tolerability]
ParticipantsCDX-3379 and Cetuximab
Incidence of Adverse Events [Safety and Tolerability]30
SecondaryTumor DNA Biomarkers.

Tumor DNA biomarkers will be evaluated and assessed for correlation with clinical efficacy. Objective response rate for subset of patients with FAT1 positive tumor is reported.

Time frame:
Tumor tissue is obtained during screening window via single biopsy procedure.
Reported as:
Count of participants · Participants
Tumor DNA Biomarkers.
ParticipantsCDX-3379 and Cetuximab
Tumor DNA Biomarkers.1

Adverse events

Collected over Adverse events were collected from initiation of treatment until 30 days after discontinuing treatment or initiation of new anti-cancer medication.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CDX-3379 and Cetuximab26/30 (86.7%)13/30 (43.3%)30/30 (100%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventCDX-3379 and Cetuximab
PneumoniaInfections and infestations3/30
DiarrhoeaGastrointestinal disorders2/30
PyrexiaGeneral disorders2/30
Lung abscessInfections and infestations1/30
InfectionInfections and infestations1/30
Urinary tract infectionInfections and infestations1/30
Small intestinal haemorrhageGastrointestinal disorders1/30
Mucosal inflammationGeneral disorders1/30
Non-cardiac chest painGeneral disorders1/30
Femoral neck fractureInjury, poisoning and procedural complications1/30
Most frequent other events
Showing 10 of 72
Most frequent other events
EventCDX-3379 and Cetuximab
DiarrhoeaGastrointestinal disorders24/30
Dermatitis acneiformSkin and subcutaneous tissue disorders17/30
HypomagnesaemiaMetabolism and nutrition disorders16/30
HypokalaemiaMetabolism and nutrition disorders14/30
FatigueGeneral disorders11/30
NauseaGastrointestinal disorders10/30
HypoalbuminaemiaMetabolism and nutrition disorders10/30
Weight decreasedInvestigations10/30
HypophosphataemiaMetabolism and nutrition disorders9/30
DysphagiaGastrointestinal disorders8/30

Baseline characteristics

Age, Continuous
Age, Continuous(years)CDX-3379 and Cetuximab
Mean62 (46 to 79)
Sex: Female, Male
Sex: Female, Male(Participants)CDX-3379 and Cetuximab
Female4
Male26
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CDX-3379 and Cetuximab
Hispanic or Latino4
Not Hispanic or Latino26
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CDX-3379 and Cetuximab
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American3
White25
More than one race0
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(participants)CDX-3379 and Cetuximab
United States30
Site of Primary Tumor
Site of Primary Tumor(Participants)CDX-3379 and Cetuximab
Pharynx/Oropharynx12
Oral Cavity11
Larynx4
Other3
Duration of Metastatic Disease
Duration of Metastatic Disease(years)CDX-3379 and Cetuximab
Mean2.2 (1 to 17)
ECOG Performance Status
ECOG Performance Status(Participants)CDX-3379 and Cetuximab
ECOG 04
ECOG 126
08

Study locations

10 sites
  • The University of Arizona Cancer Center
    Tucson, Arizona 85724, United States
  • Yale Cancer Center
    New Haven, Connecticut 06511, United States
  • Emory University Winship Cancer Institute
    Atlanta, Georgia 30322, United States
  • Rush University Medical center
    Chicago, Illinois 60612, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267, United States
  • University of Pennsylvania Hospital, Abramson Cancer Center
    Philadelphia, Pennsylvania 19104, United States
  • UPMC Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
09

References and documents

Publications

  • Duvvuri U, George J, Kim S, Alvarado D, Neumeister VM, Chenna A, Gedrich R, Hawthorne T, LaVallee T, Grandis JR, Bauman JE. Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients. Clin Cancer Res. 2019 Oct 1;25(19):5752-5758. doi: 10.1158/1078-0432.CCR-18-3453. Epub 2019 Jul 15. PubMed 31308059 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2018 to primary completion in Sep 2020, 29 months.

Results were first posted in Apr 2023, 2 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2017
First posted
Aug 21, 2017
StartActual
Mar 27, 2018
Primary completionActual
Sep 16, 2020
CompletionActual
Dec 16, 2020
Results first posted
Apr 3, 2023
Last update
Apr 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03254927
Responsible party
Sponsor
First posted
Aug 21, 2017
Start date
Mar 27, 2018
Primary completion
Sep 16, 2020
Completion
Dec 16, 2020
Results posted
Apr 3, 2023
Last update
Apr 3, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: CDX-3379 · Cetuximab

Start the discussion